Vertex Pharmaceuticals Inc (MIL:1VRTX)
€ 441.05 -2.05 (-0.46%) Market Cap: 112.08 Bil Enterprise Value: 107.49 Bil PE Ratio: 0 PB Ratio: 7.54 GF Score: 73/100

Vertex Pharmaceuticals Inc at UBS BioPharma Conference Transcript

Nov 09, 2023 / 05:00PM GMT
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst

Good afternoon, and welcome to the UBS Biopharma Conference. I'm Colin Bristow, one of the biotech analyst here. It's my pleasure to have Vertex Pharmaceuticals with us here today.

On behalf of the company, we have Charlie Wagner, CFO; and David Altshuler, the Chief Scientific Officer. So thank you both for your time today.

Questions & Answers

Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst

Maybe we can just kick off with cystic fibrosis, obviously, a sort of major franchise for you guys, continue to show impressive quarter-on-quarter growth. But from an investor perspective, it feels that this is well understood. It's pretty well modeled. As you look at consensus estimates and you speak to investors, what do you think is underappreciated about this opportunity, if anything.

Charles F. Wagner
Vertex Pharmaceuticals Incorporated - Executive VP & CFO

Yes, Colin, thanks for the question. Maybe I'll start

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot